PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer

Autor: Paola M.V. Rancoita, Laetitia Lacroix, Catherine Sautès-Fridman, Wolf H. Fridman, Massimo Freschi, Etienne Becht, Yann Vano, Alberto Briganti, Claudio Doglioni, Roberta Lucianò, Nicola Fossati, Matteo Bellone, Julien Calderaro, Francesco Montorsi, Tiffany Guédet, Florent Petitprez
Přispěvatelé: Petitprez, Florent, Fossati, Nicola, Vano, Yann, Freschi, Massimo, Becht, Etienne, Luciano, Roberta, Calderaro, Julien, Guedet, Tiffany, Lacroix, Laetitia, Rancoita, PAOLA MARIA VITTORIA, Montorsi, Francesco, Fridman, Wolf Herman, Sautes Fridman, Catherine, Briganti, Alberto, Doglioni, Claudio, Bellone, Matteo
Rok vydání: 2019
Předmět:
Zdroj: European Urology Focus. 5:192-196
ISSN: 2405-4569
DOI: 10.1016/j.euf.2017.05.013
Popis: Prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy are at higher risk of tumor recurrence and receive immediate androgen deprivation therapy (ADT). While approximately 30% of these patients do not experience recurrence, others experience disease recurrence despite ADT, and currently no biomarkers can accurately identify them. We analyzed tumors from 51 patients with node-positive prostate cancer using immunohistochemistry to investigate whether expression of the immune checkpoint ligand PD-L1 by tumor cells or the density of CD8+ or CD20+ cells are associated with clinical progression. Patients with at least 1% PD-L1+ tumor cells had shorter metastasis-free survival than those with PD-L1- tumors (p =0.008, log-rank test). Univariate Cox regression showed that patients with PD-L1+ tumors had almost four times the risk of experiencing distant metastases than those with PD-L1- tumors (hazard ratio 3.90). In addition, we found that PD-L1 expression was significantly associated with CD8+ T-cell density, but not with CD20+ B-cell density. While these results need to be confirmed in larger studies, they show that PD-L1 and CD8 may be used as biomarkers for node-positive patients at high risk of progression. The study also provides a rationale for selecting patients with node-positive PCa who might benefit the most from adjuvant immunotherapies. Patient summary: None of the available biomarkers can identify node-positive prostate cancer that will recur after surgery. We found that expression of PD-L1 by tumor cells and a high density of CD8+ T cells in tumor are associated with a higher risk of clinical progression in men with node-positive prostate cancer. Biological markers predicting tumor recurrence in node-positive prostate cancer (PCa) are currently lacking. By investigating formalin-fixed paraffin-embedded tissue sections from 51 patients with node-positive PCa, we found that patients with tumors expressing PD-L1 and/or with a higher frequency of intratumor CD8+ T cells were at the highest risk of developing PCa metastasis after surgery. These results may open new frontiers for the use of adjuvant immunotherapy in this subset of node-positive patients.
Databáze: OpenAIRE
Externí odkaz: